Format

Send to

Choose Destination
Z Rheumatol. 2016 Feb;75(1):90-6. doi: 10.1007/s00393-015-0019-5.

[Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA].

[Article in German]

Author information

1
Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland. albrecht@drfz.de.
2
Deutsches Rheuma-Forschungszentrum Berlin, Charitéplatz 1, 10117, Berlin, Deutschland.
3
Rheumapraxis Bad Aibling, Bad Aibling, Deutschland.
4
Medizinische Klinik 3, Universitätsklinikum Erlangen, Erlangen, Deutschland.
5
Poliklinik und Hiller Forschungszentrum für Rheumatologie, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Deutschland.

Abstract

OBJECTIVE:

To evaluate remission rates and therapeutic strategies in the routine care of early rheumatoid arthritis.

METHODS:

Between 2010 and 2013, a total of 1,301 patients with early arthritis were followed by 89 rheumatologists for up to 2 years in an early arthritis cohort (CAPEA). Complete 2-year data are available for 669 patients with rheumatoid arthritis.

RESULTS:

Ninety-three percent of patients were diagnosed with a moderate or high disease activity score (DAS28 > 3.2). Within 6 months, 40 % were in clinical remission (DAS28 < 2.6) and 21 % reached a low disease activity score (DAS28 > 2.6 to < 3.2). This proportion did not substantially increase during the 2-year follow-up. Methotrexate was the standard first-line treatment in 82 % of patients. During follow-up, 10 % were treated with a combination of disease-modifying antirheumatic drugs (DMARDs) and 12 % with biological agents. In 60 % of the patients who did not reach remission within 3 months (and 54 % of patients without remission by 6 months), treatment was not changed. At the beginning, 77 % of patients were treated with glucocorticoids at different starting doses (26 % < 7.5 mg, 29 % 7.5-20 mg, and 45 % ≥ 20 mg of prednisolone per day). After 2 years, 47 % remained on glucocorticoids.

CONCLUSION:

While 40 % of patients achieved clinical remission through standard care within 6 months, disease activity remained moderate to high in 37 % of patients at 2 years. In these patients a more consistent application of treatment may have increased the response rates.

KEYWORDS:

Antirheumatic agents; Combination drug therapy; Glucocorticoids; Prognosis; Treatment outcome

PMID:
26680365
DOI:
10.1007/s00393-015-0019-5
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center